Abstract Number: 0819 • ACR Convergence 2020
The Adherence Patterns Among Patients Using Infliximab Bio-originator and Biosimilar
Background/Purpose: Infliximab (INF) biosimilar was approved for multiple indications in U.S. in 2016. Although clinical trials have demonstrated that switching from infliximab bio-originator to its…Abstract Number: 1353 • ACR Convergence 2020
Achievement of Remission Is Associated with Improvement in Functionality in Certolizumab Pegol-Treated Patients with Psoriatic Arthritis, Irrespective of Pre-Existing Radiographic Structural Damage
Background/Purpose: Pre-existing structural damage in patients with psoriatic arthritis (PsA) has been suggested to impact therapeutic improvements in disease activity and functional outcomes.1,2 Here we…Abstract Number: 2010 • ACR Convergence 2020
Stable versus Tapered and Withdrawn Treatment with Tumor Necrosis Factor Inhibitor in Rheumatoid Arthritis Remission: A Randomized, Open-Label, Phase 4, Non-Inferiority Trial
Background/Purpose: Remission is the preferred treatment target in rheumatoid arthritis (RA), and many patients require biologic disease-modifying antirheumatic drugs (DMARDs) to reach this state. It…Abstract Number: 0372 • ACR Convergence 2020
Tumor Necrosis Factor-α Receptor 2 Polymorphisms and Response to TNF Inhibitor Therapy in Patients with Psoriatic Arthritis
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) have significantly improved the prognosis of patients with psoriatic arthritis (PsA); however, approximately 40% of patients do not achieve…Abstract Number: 0833 • ACR Convergence 2020
Optimized Treatment of Biological Disease Modifying Drugs in Routine Clinical Practice: Survival Study and Analysis of Patient Characteristics
Background/Purpose: The emergence of biological disease modifying drugs (bDMARD) has allowed a targeted approach to rheumatoid arthritis (RA) ("treat-to-treat" strategy). Once sustained remission is achieved,…Abstract Number: 1354 • ACR Convergence 2020
The Effect of 8 Years of TNF-α Blocking Therapy on Bone Mineral Density in Patients with Ankylosing Spondylitis
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory disease that mainly affects the axial skeleton. Bone loss reflected by low bone mineral density (BMD) is…Abstract Number: 2028 • ACR Convergence 2020
Predictors of Maintaining Inactive Disease After Etanercept Withdrawal, and Regaining Inactive Disease Status After Flare and Retreatment, in Adults with Non-radiographic Axial Spondyloarthritis: Results from RE-EMBARK
Background/Purpose: RE-EMBARK was a phase 4, multicenter, open-label, 3-period study that evaluated etanercept (ETN) withdrawal and retreatment in adult patients with non-radiographic axial spondyloarthritis (nr-axSpA)…Abstract Number: 0406 • ACR Convergence 2020
Infliximab in Refractory Uveitis Due to Behçet’s Disease: Long Term Follow-up and Therapy Optimization. Multicenter Study of 103 Caucasian Patients
Background/Purpose: Biologic therapy has improved prognosis of Behçet Disease (BD) uveitis. Although infliximab (IFX) is approved in Japan, most data in Caucasian patients comes from…Abstract Number: 0878 • ACR Convergence 2020
Absolute Lymphocyte Count Is Negatively Correlated with Atherosclerotic Cardiovascular Disease Risk Score and Red Cell Distribution Width in Psoriatic Arthritis and Increases with TNF-Inhibitor Therapy
Background/Purpose: Absolute lymphocyte count (ALC) is a parameter that represents the number of lymphocytes (B, T, and NK cells) in the blood, and lymphopenia often…Abstract Number: 1357 • ACR Convergence 2020
Comparative Efficacy of Janus Kinase Inhibitors and TNF Inhibitors in Ankylosing Spondylitis: A Network Meta-Analysis
Background/Purpose: Active ankylosing spondylitis (AS) has been associated with poor quality of life and work disability in up to 50% of patients (1). There is…Abstract Number: 0572 • ACR Convergence 2020
Two-year Cost-effectiveness Between Two Gradual Tapering Strategies in Rheumatoid Arthritis: Cost-utility Analysis of the TARA Trial
Background/Purpose: The benefits of tapering are a decreased risk of long-term adverse events and a reduction of health care costs, especially when bDMARDs are tapered.…Abstract Number: 0881 • ACR Convergence 2020
Reduction of Anterior Uveitis Flares in Patients with Axial Spondyloarthritis During Certolizumab Pegol Treatment: 96-Week Results from the C-VIEW Study
Background/Purpose: Acute anterior uveitis (AAU) is the most common extra-articular manifestation in axial spondyloarthritis (axSpA), affecting up to 40% of patients and causing significant burden.1…Abstract Number: 1358 • ACR Convergence 2020
Certolizumab Pegol Efficacy in Patients with Non-Radiographic Axial Spondyloarthritis Stratified by Baseline MRI and C-Reactive Protein Status
Background/Purpose: This post-hoc analysis from the phase 3 C-axSpAnd study aimed to evaluate whether the response to certolizumab pegol (CZP) in non-radiographic axial spondyloarthritis (nr-axSpA)…Abstract Number: 0601 • ACR Convergence 2020
The “Why” of Drug Discontinuation; Clinical Review of EMR Notes for 2,545 Patients with Rheumatic Diseases
Background/Purpose: Persistence on therapy is an important consideration in rheumatic diseases. There are multiple treatment options that influence long term disease management and a better…Abstract Number: 0883 • ACR Convergence 2020
Network Meta-Analysis of Long-Term Efficacy (ASAS40) of Biologic Disease-Modifying Anti-Rheumatic Drugs (bDMARDs) in bDMARD-Naïve Patients with Non-Radiographic Axial Spondyloarthritis
Background/Purpose: Biologic disease-modifying anti-rheumatic drugs (bDMARDs) have demonstrated large clinical improvements in patients with non-radiographic axial spondyloarthritis (nr-axSpA), with patients naïve to bDMARDs experiencing substantial…
ACR Meeting Abstracts